Keeping Track: Cloudy Horizon For Teplizumab, Roxadustat; Nuplazid Stumbles Over Subgroups; CAR-T Submissions From Gilead, J&J

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

There were more clouds than sun for drug approval prospects over the past week. The US Food and Drug Administration issued one complete response letter while signaling the potential for two more in communications with sponsors and adjusting review times for a popular drug class in the face of safety concerns.

The major approval activity was the conversion of the accelerated approval of Gilead Sciences, Inc.’s Trodelvy (sacituzumab govitecan-hziy) in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet